Summary
RMC No. 122-2020 publishes a letter from the Food and Drug Administration (FDA) clarifying the List of VAT-Exempt Drugs under Joint AO No. 2-2018.
CollapseExpand
Key points
- Content of the letter. In the letter, FDA Director Jesusa Joyce N. Cirunay clarifies certain drug products in the lists the FDA earlier gave, which were circulated through RMC No. 62-2020 and RMC No. 101-2020. The lists are based on the International Non-Proprietary Name (INN) or generic name of drug products that include salt forms.
Summary by Tax Resources PH. It is not a substitute for the full text of the issuance or professional advice.
Copies of BIR issuances are hosted here for reference. For the official version, check bir.gov.ph. Summaries by Tax Resources PH are not a substitute for the full text or professional advice.